defa14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(RULE 14A-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-12))
o Definitive Proxy Statement
o Definitive Additional Materials
þ Soliciting Material Pursuant to § 240.14a-11(c) or § 140.14a-12
BIOSCRIP, INC.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement)
Payment of Filing Fee (Check the appropriate box):
þ |
|
No fee required. |
|
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
(3) |
|
Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (set forth the
amount on which the filing fee is calculated and state how it
was determined): |
|
|
|
|
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
(5) |
|
Total fee paid: |
|
|
|
|
|
o |
|
Fee paid previously with preliminary materials. |
o |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which
the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or
Schedule and the date of its filing. |
|
(1) |
|
Amount Previously Paid: |
|
|
|
|
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
(3) |
|
Filing Party: |
|
|
|
|
|
|
|
(4) |
|
Date Filed: |
Filed by BioScrip, Inc. Pursuant to Rule 14a-12
Under the Securities Exchange Act of 1934
January 25, 2010
Dear Valued BioScrip Colleague,
We are delighted to share with you the news that BioScrip will acquire Critical
Homecare Solutions (CHS), a leading provider of home infusion and nursing services and products.
Attached is a copy of the press release issued this morning, as well as some Q&A regarding the
transaction.
The addition of CHS to the BioScrip family is an outstanding strategic fit with BioScrip, and
further accelerates our goal to be the clinical leader in the infusion, oral and injectable
specialty pharmacy services and care management programs. The acquisition will significantly add
to our national footprint with the addition of 35 infusion pharmacies, including 16 Ambulatory
Treatment Centers across 22 states. Additionally it brings 33 nursing locations, a critical asset
for our future growth and pursuit of clinical and care management excellence. BioScrip will now
have over 100 points of service, with a stronger clinical and quality infrastructure, to offer a
comprehensive and integrated solution for pharmacy and clinical management services capable of
handling all technologies.
We are confident that collectively the combined company will increase the value we deliver to all
our clients patients, payers, physicians and pharma as well as our investors. This
transaction will enhance our specialty pharmacy and home infusion
platform and enable us to
cross-sell all of our services on a national basis. This acquisition will make BioScrip a
stronger, more broadly based company, and we are eager to seize this opportunity to add to our team
of talented professionals.
The success of this acquisition will depend upon our ability to effectively integrate CHS products,
services and and most importantly employees. In the following months, we look to all of you
for ideas, collaboration and support, as well as to maintain our focus on our 2010 revenue and
earnings targets.
We want to thank each of you personally for your commitment to BioScrip and your consistent,
unyielding hard work and effort. Your dedication and professionalism have allowed us to reach the
position we enjoy today, and will enable us to reach the ambitious goals we have for BioScrip
forward.
|
|
|
Rich Friedman
|
|
Rick Smith |
Chairman & CEO
|
|
President & COO |
Additional Information and Where to Find it
BioScrip, Inc. intends to file with the Securities and Exchange Commission (the SEC) a proxy
statement regarding the issuance of stock in connection with the proposed transaction. The proxy
statement will be mailed to the stockholders of BioScrip. INVESTORS AND STOCKHOLDERS ARE ADVISED
TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY
WILL CONTAIN IMPORTANT INFORMATION ABOUT BIOSCRIP AND THE PROPOSED TRANSACTION. Investors and
stockholders may obtain free copies of these documents (when they are available) and other
documents filed with the SEC at the SECs web site at www.sec.gov. In addition, the documents
filed by BioScrip with the SEC may be obtained free of charge by contacting BioScrip, Inc.,
Investor Relations, 100 Clearbrook Road, Elmsford, NY 10523 or contacting BioScrip, Inc. Investor
Relations at 914-460-1600.
Participants in the Solicitation
BioScrip and its officers and directors may be deemed to be participants in the solicitation of
proxies from BioScrips stockholders with respect to the issuance of stock in connection with the
proposed transaction. Information about BioScrips executive officers and directors and their
ownership of BioScrips stock is set forth in the proxy statement for BioScrips 2009 Annual
Meeting of Stockholders, which was filed with the SEC on March 27, 2009. Investors and
stockholders may obtain more detailed information regarding the direct and indirect interests of
BioScrip and its respective executive officers and directors in the proposed transaction by
reading the preliminary and definitive proxy statements regarding the issuance of stock in
connection with the proposed transaction, which will be filed with the SEC.
Safe Harbor Statement
This letter includes forward-looking statements regarding the proposed acquisition and related
transactions that are not historical or current facts and deal with potential future circumstances
and developments, in particular information regarding growth opportunities, expected synergies
from the acquisition, and whether and when the transactions contemplated by the merger agreement
will be consummated. Forward-looking statements are qualified by the inherent risk and
uncertainties surrounding future expectations generally and may materially differ from actual
future experience. Risks and uncertainties that could affect forward-looking statements include:
the failure to realize synergies as a result of operational efficiencies, purchasing volume
discounts, cross-selling of services, streamlined distribution and general and administrative
reductions in the timeframe expected or at all; unexpected costs or liabilities; the result of the
review of the proposed transaction by certain regulatory agencies, and any conditions imposed in
connection with the consummation of the transaction; approval of issuance of BioScrips stock in
connection with the transaction by the stockholders of BioScrip and satisfaction of various other
conditions to the closing of the transaction contemplated by the merger agreement; and the risks
that are described from time to time in BioScrips reports filed with the Securities and Exchange
Commission (SEC), including BioScrips annual report on Form 10-K for the year ended December 31,
2008 and quarterly report on Form 10-Q for the quarter ended September 30, 2009, as amended. This
letter speaks only as of its date, and BioScrip disclaims any duty to update the information
herein.